Claudio Laudani on Comparison of Target and Non-target Vessel Revascularization for Recurrent ACS
Claudio Laudani, Cardiovascular Disease Fellow UNICT, Post-Doc Research Scholar UFHealth JAX, shared on LinkedIn:
”Patients undergoing repeat revascularization for recurrent acute coronary syndrome represent a particularly high-risk population, yet limited data exist on whether outcomes differ between target-vessel and non-target-vessel revascularization.
In our latest study from the CAST Registry, published in Journal of Cardiovascular Medicine, we analyzed 299 patients undergoing repeat PCI for ACS, and compared the long-term outcomes of patients undergoing TVR vs. non-TVR.
Alos, we explored the predictors of long-term adverse events in this high-risk population.
In our study, we found that:
- Patients undergoing repeat PCI for ACS represent a very high risk population, with most of the patients presenting with not at target LDL levels.
- This high thrombotic risk is also reflected in the follow-up event rate, as MACE rates were as high as 37% at 3 years.
- There were no significant differences between TVR and non-TVR, suggesting that recurrent ischemia is the reflection of a systematic high thrombotic burden phenotype rather than local procedure failure.
- Variables of procedural complexity were the main predictors of long-term events, including cardiogenic shock at presentation, longer fluoroscopy time, and LAD involvement.
Overall, our data highlight that patients undergoing repeat PCI require a more aggressive treatment to prevent long-term adverse events.”
Read the full article here.
Article: Long-term outcomes of percutaneous coronary intervention for recurrent events in patients undergoing target-vessel vs. nontarget-vessel revascularization
Authors: Simone Finocchiaro, Maria Sara Mauro, Claudio Laudani, Davide Landolina, Placido Maria Mazzone, Antonino Imbesi, Marco Spagnolo, Antonio Greco, Francesco Nasisi, Davide Capodanno
Stay updated on all scientific advances with Hemostasis Today.
-
May 24, 2026, 17:48Flora Peyvandi: Crucial Role of Placental ADAMTS13 in Perinatal Survival
-
May 24, 2026, 17:13Mahtab Mashayekhi: The Evolving Role of Red Blood Cell Exchange in the Management of SCD
-
May 24, 2026, 17:12Silvina Graña: Helping Families Better Understand Hemophilia and Daily Life With Bleeding Disorders
-
May 24, 2026, 17:11Miikka Vikkula: Key Insights from the ISSVA 2026 World Congress
-
May 24, 2026, 17:10Mathieu Jackson: Proud to Be Present at This Historic Moment for the Global Bleeding Disorders Community
-
May 24, 2026, 17:09Ramina Fazeli: Highlighting the Emerging Role of Neutrophil Extracellular Traps in Ovarian Cancer
-
May 24, 2026, 16:12William Wallace: Normal B12 Levels May Still Cause Brain Damage and Cognitive Decline
-
May 24, 2026, 15:54Marc Carrier: Ottawa Race Weekend Raised Over 7,000 USD for Thrombosis Canada
-
May 24, 2026, 15:44Janak Sadhu: Building a Stroke-Free Mehsana Through Community Awareness and Healthcare Collaboration